News

Somaxon also said that the FDA agreed that Silenor does not appear to cause cancer or induce genetic mutations and therefore assessment of these side effects would not

Seattle Genetics expects that SGN-33, the candidate for acute myeloid leukemia (AML) patients, will be advanced into two combination clinical trials during 2007. This will include a phase

Boehringer Ingelheim will apply Xencor's proprietary XmAb technology platform, including proprietary Fc domains, to maximize the efficacy of its antibody drug candidates against selected targets of interest. Xencor's

This is the second of several phase I studies to be conducted in order to evaluate the safety and initial efficacy of the candidate R763 in different types

Under the terms of the alliance agreement, Pharmacopeia will receive an up-front payment of $15 million and additional payments in research funding over the five-year term of the

This patent had originally been scheduled to expire in April 2010. Following this five year term extension, the patent will now expire in April 2015. Aloxi is approved

Accelerated reviews are granted to potential medicines that would represent significant improvements over current therapies. If approved by the regulatory agencies, maraviroc will be the first in a

LymphoStat-B is being developed by the companies under a definitive development and commercialization agreement entered into in August 2006. The program includes two phase III superiority trials to

“The introduction of atorvastatin in Denmark is a significant milestone in Ranbaxy's atorvastatin strategy and heralds the beginning of the company's determined efforts to bring affordable atorvastatin to